Literature DB >> 24119168

The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells.

M F Whelihan1, M J Mooberry, V Zachary, R L Bradford, K I Ataga, K G Mann, N S Key.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24119168      PMCID： PMC3992876          DOI： 10.1111/jth.12423

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  14 in total

Review 1.  Sickle cell vaso-occlusion: multistep and multicellular paradigm.

Authors:  Paul S Frenette
Journal:  Curr Opin Hematol       Date:  2002-03       Impact factor: 3.284

Review 2.  Pathophysiologic implications of membrane phospholipid asymmetry in blood cells.

Authors:  R F Zwaal; A J Schroit
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

3.  Thrombophilia in sickle cell disease: the red cell connection.

Authors:  B N Setty; A K Rao; M J Stuart
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

4.  The activation of prothrombin. II. Partial reactions, physical and chemical characterization of the intermediates of activation.

Authors:  C M Heldebrant; R J Butkowski; S P Bajaj; K G Mann
Journal:  J Biol Chem       Date:  1973-10-25       Impact factor: 5.157

5.  Meizothrombin: active intermediate formed during prothrombinase-catalyzed activation of prothrombin.

Authors:  M F Doyle; P E Haley
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

6.  Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism.

Authors:  S Krishnaswamy; W R Church; M E Nesheim; K G Mann
Journal:  J Biol Chem       Date:  1987-03-05       Impact factor: 5.157

Review 7.  The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy.

Authors:  Robert P Hebbel; Raymond Osarogiagbon; Dhananjay Kaul
Journal:  Microcirculation       Date:  2004-03       Impact factor: 2.628

8.  Erythrocyte membrane lipid reorganization during the sickling process.

Authors:  D Chiu; B Lubin; S B Shohet
Journal:  Br J Haematol       Date:  1979-02       Impact factor: 6.998

Review 9.  Hemostatic abnormalities in sickle cell disease.

Authors:  Ming Y Lim; Kenneth I Ataga; Nigel S Key
Journal:  Curr Opin Hematol       Date:  2013-09       Impact factor: 3.284

10.  Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V.

Authors:  F A Kuypers; R A Lewis; M Hua; M A Schott; D Discher; J D Ernst; B H Lubin
Journal:  Blood       Date:  1996-02-01       Impact factor: 22.113
View more
  11 in total

1.  Prospective study of sickle cell trait and venous thromboembolism incidence.

Authors:  A R Folsom; W Tang; N S Roetker; A V Kshirsagar; V K Derebail; P L Lutsey; R Naik; J S Pankow; M L Grove; S Basu; N S Key; M Cushman
Journal:  J Thromb Haemost       Date:  2014-12-11       Impact factor: 5.824

2.  Red blood cells and thrombin generation in sickle cell disease.

Authors:  Matthew F Whelihan; Ming Y Lim; Nigel S Key
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

Review 3.  Red blood cells: the forgotten player in hemostasis and thrombosis.

Authors:  J W Weisel; R I Litvinov
Journal:  J Thromb Haemost       Date:  2019-01-07       Impact factor: 5.824

Review 4.  Emerging point-of-care technologies for sickle cell disease screening and monitoring.

Authors:  Yunus Alapan; Arwa Fraiwan; Erdem Kucukal; M Noman Hasan; Ryan Ung; Myeongseop Kim; Isaac Odame; Jane A Little; Umut A Gurkan
Journal:  Expert Rev Med Devices       Date:  2016-11-22       Impact factor: 3.166

5.  Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease.

Authors:  Camille Faes; Anton Ilich; Amandine Sotiaux; Erica M Sparkenbaugh; Michael W Henderson; Laura Buczek; Joan D Beckman; Patrick Ellsworth; Denis F Noubouossie; Lantarima Bhoopat; Mark Piegore; Céline Renoux; Wolfgang Bergmeier; Yara Park; Kenneth I Ataga; Brian Cooley; Alisa S Wolberg; Nigel S Key; Rafal Pawlinski
Journal:  Blood       Date:  2019-04-05       Impact factor: 22.113

Review 6.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

7.  Hemolysis exacerbates hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis: evolving concepts of the spectrum of fibrinolysis in response to severe injury.

Authors:  Hunter B Moore; Ernest E Moore; Eduardo Gonzalez; Kirk C Hansen; Monika Dzieciatkowska; Michael P Chapman; Angela Sauaia; Bernadette West; Anirban Banerjee; Christopher C Silliman
Journal:  Shock       Date:  2015-01       Impact factor: 3.454

8.  Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.

Authors:  Yunus Alapan; Ceonne Kim; Anima Adhikari; Kayla E Gray; Evren Gurkan-Cavusoglu; Jane A Little; Umut A Gurkan
Journal:  Transl Res       Date:  2016-03-19       Impact factor: 7.012

9.  Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke.

Authors:  Hyacinth I Hyacinth; Robert J Adams; Charles S Greenberg; Jenifer H Voeks; Allyson Hill; Jacqueline M Hibbert; Beatrice E Gee
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

10.  Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

Authors:  Robert Molokie; Donald Lavelle; Michel Gowhari; Michael Pacini; Lani Krauz; Johara Hassan; Vinzon Ibanez; Maria A Ruiz; Kwok Peng Ng; Philip Woost; Tomas Radivoyevitch; Daisy Pacelli; Sherry Fada; Matthew Rump; Matthew Hsieh; John F Tisdale; James Jacobberger; Mitch Phelps; James Douglas Engel; Santhosh Saraf; Lewis L Hsu; Victor Gordeuk; Joseph DeSimone; Yogen Saunthararajah
Journal:  PLoS Med       Date:  2017-09-07       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.